FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254157051> ?p ?o ?g. }

• W4254157051 endingPage "E48" @default.
• W4254157051 startingPage "E48" @default.
• W4254157051 abstract "Recently, small randomized phase II studies have demonstrated significant improvements in progression free survival (PFS) and overall survival (OS) with the addition of stereotactic body radiation therapy (SBRT) in stage IV non-small cell lung cancer (NSCLC) patients with oligometastatic disease. Yet, current guidelines on local therapy for oligometastatic disease are lacking. The American Radium Society (ARS) Appropriate Use Criteria Thoracic Panel was assigned to create guidelines on consolidative local therapy (radiotherapy, surgery, and others) recommendations for oligometastatic and oligoprogressive NSCLC patients. A panel of radiation, medical, and surgical oncologists at academic and private practices evaluated best practice based on the current available data on the following topics/scenarios: 1) defining oligometastasis and oligoprogression, 2) role of radiation in oligometastatic disease in the up-front setting, 3) role of consolidative radiation after stable/partial response following upfront systemic therapy, 4) management of the primary and N1-N3 nodal disease, 5) role of consolidative radiation for oligoprogression during systemic therapy, 6) role of consolidative radiation for cases with targetable driver mutations, and 7) management of brain metastases in the oligometastatic or oligoprogressive setting. Based on current data and consensus by the expert panel, the optimal definition of oligometastatic and oligoprogression is ≤3 metastatic deposits, not including the primary tumor, with the understanding that ongoing trials may alter this threshold. In the scenario of radiation for oligometastatic disease in the up-front setting, several single-arm prospective trials support this approach and, therefore, this may be one feasible approach, although most contemporary randomized studies along with ongoing phase III trials are designed with standard of care systemic therapy in the upfront setting, followed by locally ablative therapy (LAT). Two randomized controlled phase 2 studies have demonstrated that the addition of local consolidative RT or surgery for oligometastatic NSCLC improved PFS and OS. Therefore, the panel supports the utilization of LAT as an option following upfront systemic therapy in oligometastatic patients. Thoracic nodal treatment is also discussed with various radiation approaches, including hypofractionation and SBRT. Prospective data on SBRT for oligoprogression are limited, but there is some suggestion that LAT may be beneficial in select patients. In patients with targetable mutations, a similar approach should be offered, although the consensus panel acknowledges a low sample size of these patients in existing trials. Lastly, the treatment of brain metastases should be based on multiple factors including the number of metastases, patient symptoms, and presence of a molecular target. The guideline topics discussed here are the first in the management of oligometastatic and oligoprogressive NSCLC based on a multidisciplinary panel of physicians. Finalized recommendations from the committee will be presented at the annual ARS meeting." @default.
• W4254157051 created "2022-05-12" @default.
• W4254157051 creator A5004625690 @default.
• W4254157051 creator A5008781374 @default.
• W4254157051 creator A5010688246 @default.
• W4254157051 creator A5012745900 @default.
• W4254157051 creator A5015170911 @default.
• W4254157051 creator A5016123864 @default.
• W4254157051 creator A5016840607 @default.
• W4254157051 creator A5022522289 @default.
• W4254157051 creator A5032441898 @default.
• W4254157051 creator A5034586842 @default.
• W4254157051 creator A5041428040 @default.
• W4254157051 creator A5063441489 @default.
• W4254157051 creator A5067536094 @default.
• W4254157051 creator A5071827540 @default.
• W4254157051 creator A5075401316 @default.
• W4254157051 creator A5080256711 @default.
• W4254157051 creator A5084735027 @default.
• W4254157051 creator A5085812198 @default.
• W4254157051 creator A5090913228 @default.
• W4254157051 date "2020-10-01" @default.
• W4254157051 modified "2023-09-25" @default.
• W4254157051 title "American Radium Society® (ARS) Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer (NSCLC)" @default.
• W4254157051 doi "https://doi.org/10.1016/j.ijrobp.2020.02.582" @default.
• W4254157051 hasPublicationYear "2020" @default.
• W4254157051 type Work @default.
• W4254157051 citedByCount "0" @default.
• W4254157051 crossrefType "journal-article" @default.
• W4254157051 hasAuthorship W4254157051A5004625690 @default.
• W4254157051 hasAuthorship W4254157051A5008781374 @default.
• W4254157051 hasAuthorship W4254157051A5010688246 @default.
• W4254157051 hasAuthorship W4254157051A5012745900 @default.
• W4254157051 hasAuthorship W4254157051A5015170911 @default.
• W4254157051 hasAuthorship W4254157051A5016123864 @default.
• W4254157051 hasAuthorship W4254157051A5016840607 @default.
• W4254157051 hasAuthorship W4254157051A5022522289 @default.
• W4254157051 hasAuthorship W4254157051A5032441898 @default.
• W4254157051 hasAuthorship W4254157051A5034586842 @default.
• W4254157051 hasAuthorship W4254157051A5041428040 @default.
• W4254157051 hasAuthorship W4254157051A5063441489 @default.
• W4254157051 hasAuthorship W4254157051A5067536094 @default.
• W4254157051 hasAuthorship W4254157051A5071827540 @default.
• W4254157051 hasAuthorship W4254157051A5075401316 @default.
• W4254157051 hasAuthorship W4254157051A5080256711 @default.
• W4254157051 hasAuthorship W4254157051A5084735027 @default.
• W4254157051 hasAuthorship W4254157051A5085812198 @default.
• W4254157051 hasAuthorship W4254157051A5090913228 @default.
• W4254157051 hasConcept C126322002 @default.
• W4254157051 hasConcept C143998085 @default.
• W4254157051 hasConcept C168563851 @default.
• W4254157051 hasConcept C19527891 @default.
• W4254157051 hasConcept C2776256026 @default.
• W4254157051 hasConcept C509974204 @default.
• W4254157051 hasConcept C71924100 @default.
• W4254157051 hasConceptScore W4254157051C126322002 @default.
• W4254157051 hasConceptScore W4254157051C143998085 @default.
• W4254157051 hasConceptScore W4254157051C168563851 @default.
• W4254157051 hasConceptScore W4254157051C19527891 @default.
• W4254157051 hasConceptScore W4254157051C2776256026 @default.
• W4254157051 hasConceptScore W4254157051C509974204 @default.
• W4254157051 hasConceptScore W4254157051C71924100 @default.
• W4254157051 hasIssue "2" @default.
• W4254157051 hasLocation W42541570511 @default.
• W4254157051 hasOpenAccess W4254157051 @default.
• W4254157051 hasPrimaryLocation W42541570511 @default.
• W4254157051 hasRelatedWork W1967103478 @default.
• W4254157051 hasRelatedWork W2032912323 @default.
• W4254157051 hasRelatedWork W2372561159 @default.
• W4254157051 hasRelatedWork W2384708512 @default.
• W4254157051 hasRelatedWork W2390152934 @default.
• W4254157051 hasRelatedWork W2395953112 @default.
• W4254157051 hasRelatedWork W2407189953 @default.
• W4254157051 hasRelatedWork W4256514411 @default.
• W4254157051 hasRelatedWork W1912371934 @default.
• W4254157051 hasRelatedWork W2156235959 @default.
• W4254157051 hasVolume "108" @default.
• W4254157051 isParatext "false" @default.
• W4254157051 isRetracted "false" @default.
• W4254157051 workType "article" @default.